Media Coverage on Recent Acquisition Announcement

Our recent transformative announcement was broadly covered in international media and industry publications  highlighting the potential of our lead candidate CDR132L in heart failure and Cardior’s position as an RNA therapy pioneer for heart disease. We thank all reporters and media outlets who have shared our story.

Novo Nordisk logo
Effective 2 May 2024,
Cardior Pharmaceuticals is a wholly-owned subsidiary
of Novo Nordisk Region Europe A/S

This will close in 0 seconds